Advertisement

Drugs

, Volume 36, Supplement 6, pp 92–101 | Cite as

Response Rate with Respect to the Blood Pressure-Lowering Effect of the Vasodilating and β-Blocking Agent Carvedilol

  • R. Rittinghausen
Studies in Hypertension

Summary

The aim of this multicentre, double-blind, randomised, controlled study was to evaluate the antihypertensive effect and to determine the response rates, safety and tolerability of 3 doses of carvedilol (25, 50 and 100mg) compared with those of pindolol 15mg, in ambulatory patients with mild to moderate uncomplicated essential hypertension. Mean supine diastolic blood pressure was the primary efficacy variable.

205 subjects between 23 and 70 years of age were randomly assigned to receive an oral dose of carvedilol or pindolol once daily for 13 weeks after a placebo run-in period of up to 4 weeks. Before administration of the study medication, blood pressure was recorded at each visit by use of the cuff method, and heart rate was counted.

The results showed similar reductions in mean supine diastolic blood pressure among all 4 treatments after 13 weeks. Carvedilol showed a good and similar response rate of approximately 84% at all doses. Heart rate was not significantly changed.

The number of patients having adverse experiences possibly related to drug therapy was 4, 16 and 15 with 25, 50 and 100mg carvedilol, respectively, and 9 with pindolol 15mg. Dizziness was the most common side effect reported for all medications. In conclusion, carvedilol 25mg appeared to be the optimum dose in the present study, displaying a high antihypertensive potency with few side effects.

Keywords

Pulse Rate Carvedilol Pindolol Adverse Experience Primary Efficacy Variable 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Eggertsen R, Sivertsson R, Andrén L, Hansson L. Haemodynamic effects of carvedilol, a new beta-adrenoceptor blocker and precapillary vasodilator in essential hypertension. Journal of Hypertension 2: 529–534, 1984PubMedCrossRefGoogle Scholar
  2. Tomlinson B, Cronin CJ, Graham BR, Prichard BNC. Haemodynamics of carvedilol in normal subjects compared with propranolol, pindolol and labetalol. Journal of Cardiovascular Pharmacology 10 (Suppl. 11): S69–S75, 1987PubMedGoogle Scholar

Copyright information

© ADIS Press Limited 1988

Authors and Affiliations

  • R. Rittinghausen
    • 1
  1. 1.Boehringer Mannheim GmbHMannheim 31Germany

Personalised recommendations